Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

The impact of age and comorbidity on survival outcomes and treatment patterns in prostate cancer

Prostate Cancer and Prostatic Diseases volume 8, pages 22–30 (2005)Cite this article

Abstract

The management of localized prostate cancer is based on stage, grade, PSA, and subjective assessment of comorbidity and life expectancy. Over the last 15 y, stage migration and the improved use of Gleason sum, PSA and TNM staging have led to many treatment options for patients with newly diagnosed localized prostate cancer. At the same time, advances in treatment techniques have helped decrease the long-term complications of surgery and radiotherapy. However, the importance of age and comorbidity, in survival outcomes and treatment decision-making has been largely overlooked. Currently, stage, grade, and PSA are the only quantifiable variables consistently used in research and treatment decision-making. Comorbidity and life expectancy have remained largely subjective variables. Increasing longevity and a rapidly aging population have made age and comorbidity increasingly important factors in clinical research and treatment decision-making. This article reviews the importance of age and comorbidity on treatment decisions and survival outcomes in prostate cancer, as well as their use as objectively quantifiable variables. Examples from the general oncology literature are given. The overview also examines validated comorbidity indices and advocates the use of the Charlson Comorbidity Index (CCI) in research outcomes and treatment decision-making in prostate cancer. Several clinical vignettes are provided to demonstrate the potential clinical utility of the CCI as applied to prostate cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Cancer facts and figures 2003. American Cancer Society Website 2003. Available at: http://www.cancer.org/downloads/STT/CAFF2003PWSecured.pdf. Accessed August 2003.

  2. SEER*Stat Database: Incidence—SEER 9 Regs, Nov 2002 Sub (1973–2000), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2003, based on the November 2002 submission. Surveillance, Epidemiology, and End Results (SEER) Program Website 2003. Available at: http://seer.cancer.gov/csr/1975_2000/results_merged/topic_age_dist.pdf. Accessed August 2003.

  3. Prostate cancer guidelines panel report on the management of clinically localized prostate cancer. American Urologic Association. Website 1995. Available at: http://www.auanet.org/timssnet/products/guidelines/main_reports/pca.pdf. Accessed August 2003.

  4. D'Amico AV et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969–974.

    Article  CAS  Google Scholar 

  5. D'Amico AV et al. Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of >4–20 ng/ml. Int J Rad Oncol Biol Phys 1997; 37: 1053–1058.

    Article  CAS  Google Scholar 

  6. Fowler JE et al. Experience with radical prostatectomy and radiation therapy for localized prostate cancer at Veterans Affairs Medical Center. J Urol 1995; 153: 1026–1031.

    Article  Google Scholar 

  7. National Cancer Institute Progress Review Groups. Defeating Prostate Cancer: Crucial Directions for Research, Report of the Prostate Cancer Progress Review Group 1998. National Cancer Institute Website 2003. Available at: http://prg.nci.nih.gov/pdfprgreports/1998prostate.pdf. Accessed August 2003.

  8. Zelefsky MJ et al. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostate cancer. J Clin Oncol 1998; 17: 517–522.

    Article  Google Scholar 

  9. Jani AB, Hellman S . Early prostate cancer: clinical decision-making. Lancet 2003; 361: 1045–1053.

    Article  Google Scholar 

  10. de Cassia Braga Ribeiro K, Kowalski LP, Latorre Mdo R . Perioperative complications, comorbidities, and survival in oropharyngeal cancer. Arch Otolaryngol Head Neck Surg 2003; 129: 219–228.

    Article  Google Scholar 

  11. Fleming ST et al. A comprehensive prognostic index to predict survival based on multiple comorbidities: a focus on breast cancer. Med Care 1999; 37: 601–614.

    Article  CAS  Google Scholar 

  12. Hall SF, Groome PA, Rothwell D . The impact of comorbidity on the survival of patients with squamous cell carcinoma of the head and neck. Head and Neck 2000; 22: 317–322.

    Article  CAS  Google Scholar 

  13. Miller DC et al. The impact of co-morbid disease on cancer control and survival following radical cystectomy. J Urol 2003; 169: 105–109.

    Article  Google Scholar 

  14. Newschaffer CJ et al. Does comorbid disease interact with cancer? An epidemiologic analysis of mortality in a cohort of elderly breast cancer patients. Gerontol A Bio Sci Med 1998; 53: 372–378.

    Article  Google Scholar 

  15. Rieker JR et al. The impact of comorbidity on the overall survival and the cause of death in patients after colorectal cancer resection. Langenbeck's Arch Surg 2002; 387: 72–76.

    Article  Google Scholar 

  16. Tammemagi CM et al. Impact of comorbidity on lung cancer survival. Int J Cancer 2003; 103: 792–802.

    Article  CAS  Google Scholar 

  17. Yancik R et al. Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study. Cancer 1998; 82: 2123–2134.

    Article  CAS  Google Scholar 

  18. Bucci J et al. Predictive factors of urinary retention following prostate brachytherapy. Int J Rad Onc Biol Phys 2002; 53: 91–98.

    Article  Google Scholar 

  19. Hegalson AR et al. Factors associated with waning sexual function among elderly men and prostate cancer patients. J Urol 1997; 158: 155–159.

    Article  Google Scholar 

  20. Liu L et al. Low acute gastrointestinal and genitourinary toxicities in whole pelvic irradiation of prostate cancer. Int J Rad Oncol Biol Phys 1997; 38: 64–71.

    Article  Google Scholar 

  21. Mantz CA et al. Potency probability following conformal megavoltage radiotherapy using conventional doses for localized prostate cancer. Int J Rad Oncol Biol Phys 1997; 37: 551–557.

    Article  CAS  Google Scholar 

  22. Yancik R . Cancer burden in the aged: an epidemiologic and demographic overview. Cancer 1997; 80: 1273–1283.

    Article  CAS  Google Scholar 

  23. Walter LC, Covinsky KE . Cancer screening in elderly patients. A framework for individualized decision making. JAMA 2001; 285: 2750–2756.

    Article  CAS  Google Scholar 

  24. Yancik R, Yates JW, Cumberlin R . Research recommendations for radiation therapy in older cancer patients. Int J Rad Oncol Biol Phys 1998; 43: 3–5.

    Google Scholar 

  25. Hébert-Crocteau N, Brisson J, Latreille C . Compliance with consensus recommendations for treatment of early stage breast carcinoma in elderly women. Cancer 1999; 85: 1104–1013.

  26. Du X, Goodwin J . Patterns of use of chemotherapy for breast cancer in older women: findings from medicare claims data. J Clin Oncol 2001; 19: 1455–1461.

    Article  CAS  Google Scholar 

  27. Donnovan JL et al. Dilemmas in treating early prostate cancer: the evidence and a questionnaire survey of consultant urologists in the United Kingdom. BMJ 1999; 318: 299–300.

    Article  Google Scholar 

  28. Mettlin CJ et al. The national cancer data base report on race, age, and region variations in prostate cancer treatment. Cancer 1997; 80: 1261–1266.

    Article  CAS  Google Scholar 

  29. Bratt O, Kristofferson U, Olsson H . Clinical course of early onset prostate cancer with special reference to family history as a prognostic factor. Eur Urol 1998; 34: 19–34.

    Article  CAS  Google Scholar 

  30. Cook GB, Watson FR . A comparison by age of death rates due to prostate cancer alone. J Urol 1968; 100: 669–671.

    Article  CAS  Google Scholar 

  31. Johnson DE, Lanieri JP, Ayala AG . Prostatic adenocarcinoma occurring in men under 50 years of age. J Surg Oncol 1972; 4: 207–216.

    Article  CAS  Google Scholar 

  32. Sandhu DP et al. Natural history and prognosis of prostate carcinoma in adolescents and men under 35 years of age. Br J Urol 1992; 69: 525–529.

    Article  CAS  Google Scholar 

  33. Aprikian AG, Zhang ZF, Fair WR . Prostate adenocarcinoma in men younger than 50 years. Cancer 1994; 74: 1768–1777.

    Article  CAS  Google Scholar 

  34. Huben R et al. Carcinoma of the prostate in men less than 50 years old. Data from the American College of Surgeon's National Survey. Urology 1982; 20: 585–588.

    Article  CAS  Google Scholar 

  35. Parker CC, Gospodarowicz M, Warde P . Does age influence the behaviour of localized prostate cancer? BJU Int 2001; 87: 629–637.

    Article  CAS  Google Scholar 

  36. Alexander RB et al. Pathologic stage is higher in older men with clinical stage B1 adenocarcinoma of the prostate. J Urol 1989; 141: 586–587.

    Article  Google Scholar 

  37. Carter HB, Epstein JI, Partin AW . Influence of age and prostate-specific antigen on the change of curable prostate cancer among men with nonpalpable disease. Urology 1999; 53: 126–130.

    Article  CAS  Google Scholar 

  38. D'Amico AV et al. Advanced age at diagnosis is an independent predictor of time to death from prostate carcinoma for patients undergoing external beam radiation therapy for clinically localized prostate carcinoma. Cancer 2003; 97: 56–62.

    Article  Google Scholar 

  39. Heart disease and stroke statistics—2003 update. American Heart Association Website 2003. Available at: http://www.americanheart.org/downloadable/heart/10590179711482003HDSStatsBookREV7-03.pdf. Accessed July 2003.

  40. Chang AM, Halter JB . Aging and insulin secretion. Am J Physiol Endocrinol Metab 2003; 284: E7–E12.

    Article  CAS  Google Scholar 

  41. Staessen JA et al. Essential hypertension. Lancet 2003; 316: 1629–1641.

    Article  Google Scholar 

  42. Coebergh JWW et al. Serious co-morbidity among unselected cancer patients newly diagnosed in the Southeastern part of the Netherlands in 1993–1996. J Clinical Epidemiol 1999; 52: 1131–1136.

    Article  CAS  Google Scholar 

  43. Newschaffer CJ et al. Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. J Natl Cancer Inst 2000; 92: 613–621.

    Article  CAS  Google Scholar 

  44. Satariano WA, Ragland KE, Van Den Eeden SK . Cause of death in men diagnosed with prostate cancer. Cancer 1998; 83: 1180–1188.

    Article  CAS  Google Scholar 

  45. Post PN et al. The independent prognostic value of comorbidity among men aged <75 years with localized prostate cancer: a population-based study. BJU Int 2001; 63: 821–826.

    Google Scholar 

  46. Fowler JE, Terrell FL, Refroe LC . Co-morbidities and survival of men with localized prostate cancer treated with surgery or radiation therapy. J Urol 1996; 156: 1714–1718.

    Article  Google Scholar 

  47. Albertsen PC et al. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998; 280: 975–980.

    Article  CAS  Google Scholar 

  48. Sweat SD et al. Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical gleason score and patient age. J Urol 2002; 168: 525–529.

    Article  Google Scholar 

  49. Carlson KV, Nitti VW . Prevention and management of incontinence following radical prostatectomy. Urol Clin North Am 2001; 28: 595–612.

    Article  CAS  Google Scholar 

  50. Eastham JA et al. Risk factors for urinary incontinence after radical prostatectomy. J Urol 1996; 156: 1707–1713.

    Article  CAS  Google Scholar 

  51. de Groot V et al. How to measure comorbidity: a critical review of available methods. J Clin Epidemiol 2003; 56: 221–229.

    Article  Google Scholar 

  52. Exterman M et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998; 16: 1582–1587.

    Article  Google Scholar 

  53. Extermann M . Measuring comorbidity in older cancer patients. Eur J Cancer 2000; 36: 453–471.

    Article  CAS  Google Scholar 

  54. Liu M, Domen K, Chino N . Comorbidity measures for stroke outcome research: a preliminary study. Arch Phys Med Rehab 1997; 78: 166–172.

    Article  CAS  Google Scholar 

  55. Newschaffer CJ, Bush TL, Penbarthy LT . Comorbidity measurement in elderly female breast cancer patients with administrative and medical records data. J Clin Epidmeiol 1997; 50: 725–733.

    Article  CAS  Google Scholar 

  56. Katz JN et al. Can comorbidity be measured by questionnaire rather than medical record review? Med Care 1996; 34: 1093–1101.

    Article  Google Scholar 

  57. Charlson ME et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987; 40: 373–383.

    Article  CAS  Google Scholar 

  58. Krousel-Wood MA, Abdoh A, Re R . Comparing comorbid-illness indices assessing outcome variation: the case of prostatectomy. J Gen Intern Med 1996; 11: 32–38.

    Article  CAS  Google Scholar 

  59. Clemens JD et al. A new clinical anatomic staging system for evaluating prognosis and treatment of prostate cancer. J Chron Dis 1986; 39: 913–928.

    Article  CAS  Google Scholar 

  60. Piccirillo JF . Inclusion of comorbidity in a staging system for head and neck cancer. Oncology 1995; 9: 831–836.

    CAS  PubMed  Google Scholar 

  61. Post PN et al. Comorbidity in patients with prostate cancer and its relevance to treatment choice. BJU Int 1999; 84: 652–656.

    Article  CAS  Google Scholar 

  62. Albertsen PC et al. The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol 1996; 156: 127–132.

    Article  CAS  Google Scholar 

  63. Johnstone PAS et al. Effect of age on biochemical disease-free outcome in patients with T1-3 prostate cancer treated with definitive radiotherapy in an equal-access health care system: a radiation oncology report of the department of defense center for prostate disease research. Int J Rad Onc Biol Phys 2003; 55: 964–969.

    Article  Google Scholar 

  64. Morandi U et al. Results of surgical resection in patients over the age of 70 years with non small-cell lung cancer. Eur J Cardiothorac Surg 1997; 11: 432–439.

    Article  CAS  Google Scholar 

  65. Pagni S et al. Pulmonary resection for malignancy in the elderly: is age still a risk factor? Eur J Cardiothorac Surg 1998; 14: 40–44.

    Article  CAS  Google Scholar 

  66. Roxburg JC, Thompson J, Goldstraw P . Hospital mortality and long-term survival after pulmonary resection in the elderly. Ann Thorac Surg 1991; 51: 800–803.

    Article  Google Scholar 

  67. Birim Ö et al. Validation of the Charlson comorbidity index in patients with operated primary non-small cell lung cancer. Eur J Cardiothorac Surg 2003; 23: 30–34.

    Article  CAS  Google Scholar 

  68. Blute ML et al. Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol 2000; 164: 1591–1595.

    Article  CAS  Google Scholar 

  69. Partin AW et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997; 277: 1445–1451.

    Article  CAS  Google Scholar 

  70. Partin AW et al. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 2001; 58: 843–848.

    Article  CAS  Google Scholar 

  71. Ung JO et al. Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. Urology 2002; 60: 458–463.

    Article  Google Scholar 

  72. Han M et al. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol 2001; 166: 416–419.

    Article  CAS  Google Scholar 

  73. Farkas A et al. National trends in the epidemiology of prostate cancer, 1973 to 1994: evidence for the effectiveness of prostate-specific antigen screening. Urology 1998; 52: 444–448.

    Article  CAS  Google Scholar 

  74. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet 1999; 353: 2001–2073.

  75. The Captopril-Digoxin Multicentre Research Group. Comparative effects of therapy with captopril and digoxin in mild to moderate heart failure. JAMA 1988; 259: 539–544.

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, UC Davis Cancer Center, University of California, Davis, Sacramento, California, USA

    W H Hall, J K Ryu, S Narayan & S Vijayakumar

  2. Department of Radiation and Cellular Oncology, University of Chicago, Chicago, Illinois, USA

    A B Jani

Authors
  1. W H Hall
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A B Jani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J K Ryu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Narayan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Vijayakumar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S Vijayakumar.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hall, W., Jani, A., Ryu, J. et al. The impact of age and comorbidity on survival outcomes and treatment patterns in prostate cancer. Prostate Cancer Prostatic Dis 8, 22–30 (2005). https://doi.org/10.1038/sj.pcan.4500772

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500772

Keywords

This article is cited by

Search

Advanced search

Quick links